Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review

被引：1

作者：

Zhu, Peng-Fei ^{[1
,2
]}

Chen, Yun-Wang ^{[2
,3
]}

Wang, Ming-Xing ^{[1
,2
]}

Deng, Ya-Ya ^{[2
,3
]}

Pan, Shuang-Yue ^{[2
]}

Chen, Zhe-Ling ^{[2
]}

Yang, Liu ^{[1
,2
]}

机构：

[1] Bengbu Med Coll, Grad Sch Clin Med, Bengbu, Anhui, Peoples R China

[2] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Canc Ctr, Dept Med Oncol,Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China

[3] Qingdao Univ, Med Coll, Qingdao, Shandong, Peoples R China

来源：

ANTI-CANCER DRUGS | 2022年 / 33卷 / 01期

关键词：

case report; chemotherapy; immunotherapy; pancreatic cancer; PD-1; tumor mutational burden; CTLA-4; BLOCKADE; PD-1; PEMBROLIZUMAB; SENSITIVITY; GEMCITABINE; INHIBITION; FOLFIRINOX; LANDSCAPE; SURVIVAL; ANTIBODY;

D O I：

10.1097/CAD.0000000000001232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy.

引用

页码：E822 / E827

页数：6

共 43 条

[1]

Adamska Aleksandra, 2018, Advances in Biological Regulation, V68, P77, DOI 10.1016/j.jbior.2017.11.007

[2] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[3] The molecular basis of pancreatic fibrosis - Common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma [J].

Binkley, CE ;

Zhang, LZ ;

Greenson, JK ;

Giordano, TJ ;

Kuick, R ;

Misek, D ;

Hanash, S ;

Logsdon, CD ;

Simeone, DM .

PANCREAS, 2004, 29 (04) :254-263

[4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[5]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[6] Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [J].

Chabanon, Roman M. ;

Pedrero, Marion ;

Lefebvre, Celine ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Postel-Vinay, Sophie .

CLINICAL CANCER RESEARCH, 2016, 22 (17) :4309-4321

[7] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].

Chan, T. A. ;

Yarchoan, M. ;

Jaffee, E. ;

Swanton, C. ;

Quezada, S. A. ;

Stenzinger, A. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56

[8] Correction: Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma [J].

Chan, Timothy A. ;

Wolchok, Jedd D. ;

Snyder, Alexandra .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) :1984-1984

[9] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].

Cloughesy, Timothy F. ;

Mochizuki, Aaron Y. ;

Orpilla, Joey R. ;

Hugo, Willy ;

Lee, Alexander H. ;

Davidson, Tom B. ;

Wang, Anthony C. ;

Ellingson, Benjamin M. ;

Rytlewski, Julie A. ;

Sanders, Catherine M. ;

Kawaguchi, Eric S. ;

Du, Lin ;

Li, Gang ;

Yong, William H. ;

Gaffey, Sarah C. ;

Cohen, Adam L. ;

Mellinghoff, Ingo K. ;

Lee, Eudocia Q. ;

Reardon, David A. ;

O'Brien, Barbara J. ;

Butowski, Nicholas A. ;

Nghiemphu, Phioanh L. ;

Clarke, Jennifer L. ;

Arrillaga-Romany, Isabel C. ;

Colman, Howard ;

Kaley, Thomas J. ;

De Groot, John F. ;

Liau, Linda M. ;

Wen, Patrick Y. ;

Prins, Robert M. .

NATURE MEDICINE, 2019, 25 (03) :477-+

[10] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

← 1 2 3 4 5 →